Δ9-Tetrahydrocannabinol and cannabidiol modulate mitogen-induced tryptophan degradation and neopterin formation in peripheral blood mononuclear cells in vitro

Journal of Neuroimmunology

Volumn 207, Issue 1-2, 2009, Pages 75-82

  Jenny, Marcel ^a   Santer, Elisabeth ^a   Pirich, Eberhard ^b   Schennach, Harald ^c   Fuchs, Dietmar ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Bionorica Research GmbH   (Austria)

^c UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

9 Tetrahydrocannabinol; Cannabidiol; Indoleamine 2,3 dioxygenase; Neopterin; PBMC; THP 1

Indexed keywords

CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DRONABINOL; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; NEOPTERIN; SEROTONIN; TRYPTOPHAN; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; ALPHA INTERFERON; CANNABINOID RECEPTOR; INDOLE DERIVATIVE; IODOPRAVADOLINE; KYNURENINE; LIPOPOLYSACCHARIDE; MITOGENIC AGENT; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; TETRAHYDROCANNABINOL;

ARTICLE; CELL LINE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MONONUCLEAR CELL; NONPARAMETRIC TEST;

CANNABIDIOL; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GENE EXPRESSION REGULATION; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INDOLES; INTERFERON-ALPHA; KYNURENINE; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MITOGENS; MORPHOLINES; NEOPTERIN; PYRAZOLES; RECEPTORS, CANNABINOID; STATISTICS, NONPARAMETRIC; TETRAHYDROCANNABINOL; TRYPTOPHAN;

EID: 60149102476     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.12.004     Document Type: Article

References (59)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (1994) Washington, DC (1994)
2. Beal J.E., Olson R., Lefkowitz L., Laubenstein L., Bellman P., Yangco B., Morales J.O., Murphy R., Powderly W., Plasse T.F., Mosdell K.W., and Shepard K.V. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J. Pain Symptom. Manage. 14 (1997) 7-14
3. Berdyshev E.V. Cannabinoid receptors and the regulation of immune response. Chem. Phys. Lipids 108 (2000) 169-190
4. Bouaboula M., Rinaldi M., Carayon P., Carillon C., Delpech B., Shire D., LeFur G., and Casellas P. Cannabinoid-receptor expression in human leukocytes. Eur. J. Biochem. 214 (1993) 173-180
5. Capuron L., Neurauter G., Musselman D.L., Lawson D.H., Nemeroff C.B., and Fuchs D. Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol. Psychiatry 54 (2003) 906-914
6. Carlisle S.J., Marciano-Cabral F., Staab A., Ludwick C., and Cabral G.A. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int. Immunopharmacol. 2 (2002) 69-82
7. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22 (1984) 27-55
8. Christensen R., Kristensen P.K., Bartels E.M., Bliddal H., and Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370 (2007) 1706-1713
9. Daaka Y., Friedman H., and Klein T.W. Cannabinoid receptor proteins are increased in Jurkat, human T-cell line after mitogen activation. J. Pharmacol. Exp. Ther. 276 (1996) 776-783
10. Degenhardt L., Hall W., and Lynskey M. Exploring the association between cannabis use and depression. Addiction 98 (2003) 1493-1504
11. Di Marzo V., De Petrocellis L., and Bisogno T. The biosynthesis, fate and pharmacological properties of endocannabinoids. Handb. Exp. Pharmacol. 168 (2005) 147-185
12. Fischer-Stenger K., Dove Pettit D.A., and Cabral G.A. Delta 9-tetrahydrocannabinol inhibition of tumor necrosis factor-alpha: suppression of post-translational events. J. Pharmacol. Exp. Ther. 267 (1993) 1558-1565
13. Galiègue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., Bouaboula M., Shire D., Le Fur G., and Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232 (1995) 54-61
14. Gobbi G., Bambico F.R., Mangieri R., Bortolato M., Campolongo P., Solinas M., Cassano T., Morgese M.G., Debonnel G., Duranti A., Tontini A., Tarzia G., Mor M., Trezza V., Goldberg S.R., Cuomo V., and Piomelli D. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18620-18625
15. Griebel G., Stemmelin J., and Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiatry 57 (2005) 261-267
16. Gruber A.J., Pope H.G., and Brown M.E. Do patients use marijuana as an antidepressant?. Depression 4 (1996) 77-80
17. Hill M.N., and Gorzalka B.B. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?. Behav. Pharmacol. 16 (2005) 333-352
18. Huber C., Batchelor J.R., Fuchs D., Hausen A., Lang A., Niederwieser D., Reibnegger G., Swetly P., Troppmair J., and Wachter H. Immune response-associated production of neopterin - release from macrophages primarily under control of interferon-gamma. J. Exp. Med. 160 (1984) 310-316
19. Huang A., Fuchs D., Widner B., Glover C., Henderson D.C., and Allen-Mersh T.G. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br. J. Cancer 86 (2002) 1691-1696
20. Kaminski N.E. Immune regulation by cannabinoid compounds through the inhibition of the cyclic AMP signaling cascade and altered gene expression. Biochem. Pharmacol. 52 (1996) 1133-1140
21. Kawakami Y., Klein T.W., Newton C., Djeu J.Y., Specter S., and Friedman H. Suppression by delta-9-tetrahydrocannabinol of interleukin 2-induced lymphocyte proliferation and lymphokine-activated killer cell activity. Int. J. Immunopharmacol. 10 (1988) 485-488
22. Klein T.W., Newton C.A., Widen R., and Friedman H. The effect of delta-9-tetrahydrocannabinol and 11-hydroxy-delta-9-tetrahydrocannabinol on T-lymphocyte and B-lymphocyte mitogen responses. J. Immunopharmacol. 7 (1985) 451-466
23. Klein T.W., Lane B., Newton C.A., and Friedman H. The cannabinoid system and cytokine network. Proc. Soc. Exp. Biol. Med. 225 (2000) 1-8
24. Kusher D.I., Dawson L.O., Taylor A.C., and Djeu J.Y. Effect of the psychoactive metabolite of marijuana, delta 9-tetrahydrocannabinol (THC), on the synthesis of tumor necrosis factor by human large granular lymphocytes. Cell. Immunol. 154 (1994) 99-108
25. Matsuda L.A., Lolait S.J., Brownstein M.J., Young C.A., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (Lond). 346 (1990) 561-564
26. McCoy K.L., Gainey D., and Cabral G.A. delta 9-Tetrahydrocannabinol modulates antigen processing by macrophages. J. Pharmacol. Exp. Ther. 273 (1995) 1216-1223
27. Medveczky M.M., Sherwood T.A., Klein T.W., Friedman H., and Medveczky P.G. Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpesviruses in vitro. BMC Med. 15 (2004) 2-34
28. Molina-Holgado F., Molina-Holgado E., Leret M.L., Gonzalez M.I., and Reader T.A. Distribution of indoleamines and [3H]paroxetine binding in rat brain regions following acute or perinatal delta 9-tetrahydrocannabinol treatments. Neurochem. Res. 18 (1993) 1183-1191
29. Morales M. Cannabinoids and the central serotonergic system. In: Onaivi E., Sugiura T., and Di Marzo I. (Eds). Endocannabinoids: the Brain and Body's Marijuana and Beyond (2006), Taylor & Francis, Boca Raton 249-260
30. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
31. Murr C., Widner B., Wirleitner B., and Fuchs D. Neopterin as a marker for immune system activation. Curr. Drug Metab. 3 (2002) 175-187
32. Noe S.N., Newton C., Widen R., Friedman H., and Klein T.W. Anti-CD40, anti-CD3, and IL-2 stimulation induce contrasting changes in CB1 mRNA expression in mouse splenocytes. J. Neuroimmunol. 110 (2000) 161-167
33. Nong L., Newton C., Cheng Q., Friedman H., Roth M.D., and Klein T.W. Altered cannabinoid receptor mRNA expression in peripheral blood mononuclear cells from marijuana smokers. J. Neuroimmunol. 127 (2002) 169-176
34. Pacher P., and Kecskemeti V. Trends in the development of new antidepressants. Is there a light at the end of the tunnel?. Curr. Med. Chem. 11 (2004) 925-943
35. Pacher P., Bátkai S., and Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 58 3 (2006) 389-462
36. Petit-Demouliere B., Chenu F., and Bourin M. Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology (Berlin) 177 (2005) 245-255
37. Pertwee R.G. In: Di Marzo V. (Ed). The pharmacology and therapeutic potential of cannabidiol (2004), Kluwer-Plenum, Cannabinoids 32-83
38. Pertwee R.G. Cannabidiol as a potential medicine. In: Mechoulam R. (Ed). Cannabinoids as Therapeutics (2005), Birkhauser Verlag, Basel 47-65
39. Pertwee R.G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br. J. Pharmacol. 153 2 (2008) 199-215
40. Pross S.H., Nakano Y., Widen R., McHugh S., Newton C.A., Klein T.W., and Friedman H. Differing effects of delta-9-tetrahydrocannabinol (THC) on murine spleen cell populations dependent upon stimulators. Int. J. Immunopharmacol. 14 (1992) 1019-1027
41. Robson P. Therapeutic aspects of cannabis and cannabinoids. Br. J. Psychiatry 178 (2001) 107-115
42. Russo E., and Guy G.W. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med. Hypotheses 66 (2006) 234-246
43. Russo S., Kema I.P., Fokkema M.R., Boon J.C., Willemse P.H., De Vries E.G., Den Boer J.A., and Korf J. Tryptophan as a link between psychopathology and somatic states. Psychosom. Med. 65 (2003) 665-671
44. Rutkowska M., and Jachimczuk O. Antidepressant-like properties of ACEA (arachidonyl-2-chloroethylamide), the selective agonist of CB1 receptors. Acta Pol. Pharm. 61 (2004) 165-167
45. Sagredo O., Ramos J.A., Fernández-Ruiz J., Rodriguez M.L., and De Miguel R. Chronic Delta9-tetrahydrocannabinol administration affects serotonin levels in the rat frontal cortex. Naunyn-Schmiedeberg's Arch. Pharmacol. 372 (2006) 313-317
46. Schatz A.R., Lee M., Condie R.B., Pulaski J.T., and Kaminski N.E. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol. Appl. Pharmacol. 142 (1997) 278-287
47. Schroecksnadel K., Wirleitner B., Winkler C., and Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin. Chim. Acta. 364 (2006) 82-90
48. Srivastava M.D., Srivastava B.I., and Brouhard B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 40 (1998) 179-185
49. Thomas A., Baillie G.L., Phillips A.M., Razdan R.K., Ross R.A., and Pertwee R.G. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br. J. Pharmacol. 150 (2007) 613-623
50. Tzavara E.T., Davis R.J., Perry K.W., Li X., Salhoff C., Bymaster F.P., Witkin J.M., and Nomikos G.G. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br. J. Pharmacol. 138 (2003) 544-553
51. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., Stella N., Makriyannis A., Piomelli D., Davison J.S., Marnett L.J., Di Marzo V., Pittman Q.J., Patel K.D., and Sharkey K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 (2005) 329-332
52. Ware M.A., Adams H., and Guy G.W. The medicinal use of cannabis in the UK: results of a nationwide survey. Int. J. Clin. Pract. 59 (2005) 291-295
53. Watzl B., Scuderi P., and Watson R.R. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-γ and suppress interleukin-1 in vitro. Int. J. Immunopharmacol. 13 (1991) 1091-1097
54. Widner B., Werner E.R., Schennach H., Wachter H., and Fuchs D. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin. Chem. 43 (1997) 2424-2426
55. Widner B., Laich A., Sperner-Unterweger B., Ledochowski M., and Fuchs D. Neopterin production tryptophan degradation and mental depression: what is the link?. Brain. Behav. Immun. 16 (2002) 590-595
56. Winkler C., Schroecksnadel K., Schennach H., and Fuchs D. Vitamin C and E suppress mitogen-stimulated peripheral blood mononuclear cells in vitro. Int. Arch. Allergy Immunol. 142 (2007) 127-132
57. Wirleitner B., Neurauter G., Schroecksnadel K., Frick B., and Fuchs D. Interferon-γ-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr. Med. Chem. 10 (2003) 1581-1591
58. Young S.N., and Leyton M. The role of serotonin in human mood and social interaction. Insight from altered tryptophan levels. Pharmacol. Biochem. Behav. 71 (2002) 857-865
59. Yuan M., Kiertscher S.M., Cheng Q., Zoumalan R., Tashkin D.P., and Roth M.D. D9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J. Neuroimmunol. 133 (2002) 124-131